Search

Your search keyword '"Chapuis, Nicolas"' showing total 416 results
Start Over Author "Chapuis, Nicolas"
416 results on '"Chapuis, Nicolas"'

1. Loss of hematopoietic progenitors heterogeneity is an adverse prognostic factor in lower-risk myelodysplastic neoplasms

Author

Dussiau, Charles, Comont, Thibault, Knosp, Camille, Vergnolle, Inès, Bravetti, Clotilde, Canali, Alban, Houvert, Amandine, Largeaud, Laetitia, Daveaux, Christian, Zaroili, Laila, Friedrich, Chloé, Boussaid, Ismaël, Zalmai, Loria, Almire, Carole, Rauzy, Odile, Willems, Lise, Birsen, Rudy, Bouscary, Didier, Fontenay, Michaela, Kosmider, Olivier, Chapuis, Nicolas, and Vergez, François

Published
2024
Full Text
View/download PDF

2. Flow cytometric analysis of erythroid precursors and mutational signatures of lower risk myelodysplastic syndromes identify responders to erythroid stimulating agents

Author

Raddi, Marco G., Bencini, Sara, Peruzzi, Benedetta, Mattiuz, Giorgio, De Pourcq, Sven, Tanturli, Michele, Chapuis, Nicolas, Consagra, Angela, Rigodanza, Luca, Amato, Cristina, Sanna, Alessandro, Tofacchi, Elena, Attardi, Enrico, Park, Sophie, Kosmider, Olivier, Annunziato, Francesco, Fontenay, Michaela, and Santini, Valeria

Published
2024
Full Text
View/download PDF

3. Accelerated DNA replication fork speed due to loss of R-loops in myelodysplastic syndromes with SF3B1 mutation

Author

Rombaut, David, Lefèvre, Carine, Rached, Tony, Bondu, Sabrina, Letessier, Anne, Mangione, Raphael M., Farhat, Batoul, Lesieur-Pasquier, Auriane, Castillo-Guzman, Daisy, Boussaid, Ismael, Friedrich, Chloé, Tourville, Aurore, De Carvalho, Magali, Levavasseur, Françoise, Leduc, Marjorie, Le Gall, Morgane, Battault, Sarah, Temple, Marie, Houy, Alexandre, Bouscary, Didier, Willems, Lise, Park, Sophie, Raynaud, Sophie, Cluzeau, Thomas, Clappier, Emmanuelle, Fenaux, Pierre, Adès, Lionel, Margueron, Raphael, Wassef, Michel, Alsafadi, Samar, Chapuis, Nicolas, Kosmider, Olivier, Solary, Eric, Constantinou, Angelos, Stern, Marc-Henri, Droin, Nathalie, Palancade, Benoit, Miotto, Benoit, Chédin, Frédéric, and Fontenay, Michaela

Published
2024
Full Text
View/download PDF

6. RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia

Author

Decroocq, Justine, Birsen, Rudy, Montersino, Camille, Chaskar, Prasad, Mano, Jordi, Poulain, Laury, Friedrich, Chloe, Alary, Anne-Sophie, Guermouche, Helene, Sahal, Ambrine, Fouquet, Guillemette, Gotanègre, Mathilde, Simonetta, Federico, Mouche, Sarah, Gestraud, Pierre, Lescure, Auriane, Del Nery, Elaine, Bosc, Claudie, Grenier, Adrien, Mazed, Fetta, Mondesir, Johanna, Chapuis, Nicolas, Ho, Liza, Boughalem, Aicha, Lelorc’h, Marc, Gobeaux, Camille, Fontenay, Michaela, Recher, Christian, Vey, Norbert, Guillé, Arnaud, Birnbaum, Daniel, Hermine, Olivier, Radford-Weiss, Isabelle, Tsantoulis, Petros, Collette, Yves, Castellano, Rémy, Sarry, Jean-Emmanuel, Pasmant, Eric, Bouscary, Didier, Kosmider, Olivier, and Tamburini, Jerome

Published
2022
Full Text
View/download PDF

7. White blood cells scattergram as a valuable tool for COVID‐19 screening: A multicentric study.

Author

Osman, Jennifer, Gonnin, Cécile, Lambert, Jérome, Behier, Céline, Chapuis, Nicolas, Chevalier, Simon, Debus, Jérôme, Delaval, Anne, Depoorter, Maxime, Dumas, Cécile, Dumesges, Amély, Dussert, Pascale, Vacher, Corinne Ferrero, Dubois‐Galopin, Frédérique, Gerard, Delphine, Bollotte, Pauline Gravière, Guignedoux, Geoffroy, Mayeur‐Rousse, Caroline, Mercier‐Bataille, Delphine, and Ronez, Emily

Subjects
LYMPHOCYTE classification, LEUCOCYTES, STATISTICAL models, PREDICTIVE tests, ADULT respiratory distress syndrome, COVID-19 testing, LYMPHOPENIA, RETROSPECTIVE studies, DESCRIPTIVE statistics, INFLUENZA, HEMATOLOGY, MEDICAL records, ACQUISITION of data, RESEARCH, MEDICAL screening, COVID-19, SENSITIVITY & specificity (Statistics), SYMPTOMS
Abstract

Introduction: New tools have been developed to distinguish the COVID‐19 diagnosis from other viral infections presenting similar symptomatology and mitigate the lack of sensitivity of molecular testing. We previously identified a specific "sandglass" aspect on the white blood cells (WBC) scattergram of COVID‐19 patients, as a highly reliable COVID‐19 screening test (sensitivity: 85.9%, specificity: 83.5% and positive predictive value: 94.3%). We then decided to validate our previous data in a multicentric study. Methods: This retrospective study involved 817 patients with flu‐like illness, among 20 centers, using the same CBC instrument (XN analyzer, SYSMEX, Japan). After training, one specialist per center independently evaluated, under the same conditions, the presence of the "sandglass" aspect of the WDF scattergram, likely representing plasmacytoid lymphocytes. Results: Overall, this approach showed sensitivity: 59.0%, specificity: 72.9% and positive predictive value: 77.7%. Sensitivity improved with subgroup analysis, including in patients with lymphopenia (65.2%), patients presenting symptoms for more than 5 days (72.3%) and in patients with ARDS (70.1%). COVID‐19 patients with larger plasmacytoid lymphocyte cluster (>15 cells) more often have severe outcomes (70% vs. 15% in the control group). Conclusion: Our findings confirm that the WBC scattergram analysis could be added to a diagnostic algorithm for screening and quickly categorizing symptomatic patients as either COVID‐19 probable or improbable, especially during COVID‐19 resurgence and overlapping with future influenza epidemics. The observed large size of the plasmacytoid lymphocytes cluster appears to be a hallmark of COVID‐19 patients and was indicative of a severe outcome. Furthers studies are ongoing to evaluate the value of the new hematological parameters in combination with WDF analysis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects

Author

Smadja, David M., Mentzer, Steven J., Fontenay, Michaela, Laffan, Mike A., Ackermann, Maximilian, Helms, Julie, Jonigk, Danny, Chocron, Richard, Pier, Gerald B., Gendron, Nicolas, Pons, Stephanie, Diehl, Jean-Luc, Margadant, Coert, Guerin, Coralie, Huijbers, Elisabeth J. M., Philippe, Aurélien, Chapuis, Nicolas, Nowak-Sliwinska, Patrycja, Karagiannidis, Christian, Sanchez, Olivier, Kümpers, Philipp, Skurnik, David, Randi, Anna M., and Griffioen, Arjan W.

Published
2021
Full Text
View/download PDF

9. Optical genome mapping refines cytogenetic diagnostics, prognostic stratification and provides new molecular insights in adult MDS/AML patients

Author

Balducci, Estelle, Kaltenbach, Sophie, Villarese, Patrick, Duroyon, Eugénie, Zalmai, Loria, Friedrich, Chloé, Suarez, Felipe, Marcais, Ambroise, Bouscary, Didier, Decroocq, Justine, Birsen, Rudy, Fontenay, Michaëla, Templé, Marie, Brouzes, Chantal, Touzart, Aurore, Steimlé, Thomas, Cieslak, Agata, Lhermitte, Ludovic, Almire, Carole, Chapuis, Nicolas, Hermine, Olivier, Asnafi, Vahid, Kosmider, Olivier, and Couronné, Lucile

Published
2022
Full Text
View/download PDF

10. Along with PaO2/FiO2 ratio and lymphopenia, low HLA-DR monocytes are the only additional parameter that independently predicts the clinical course of undifferentiated SARS-CoV-2 patients in emergency departments

Author

Lafon, Thomas, primary, Chapuis, Nicolas, additional, Guerin, Estelle, additional, Daix, Thomas, additional, Otranto, Marcela, additional, Boumediene, Ahmed, additional, Jeannet, Robin, additional, Fontenay, Michaela, additional, Karam, Henri Hani, additional, Vignon, Philippe, additional, Monneret, Guillaume, additional, François, Bruno, additional, Jais, Jean-Philippe, additional, and Feuillard, Jean, additional

Published
2024
Full Text
View/download PDF

11. Along with PaO2/FiO2 ratio and lymphopenia, low HLA-DR monocytes are the only additional parameter that independently predicts the clinical course of undifferentiated SARS-CoV-2 patients in emergency departments.

Author

Lafon, Thomas, Chapuis, Nicolas, Guerin, Estelle, Daix, Thomas, Otranto, Marcela, Boumediene, Ahmed, Jeannet, Robin, Fontenay, Michaela, Hani, Karam Henri, Vignon, Philippe, Monneret, Guillaume, François, Bruno, Jean-Philippe, Jais, and Feuillard, Jean

Subjects
HLA-DR antigens, HOSPITAL emergency services, SARS-CoV-2, LYMPHOPENIA, MONOCYTES
Abstract

Because one-third of patients deteriorate after their admission to the emergency department, assessing the prognosis of COVID-19 patients is of great importance. However, to date, only lymphopenia and the partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) ratio have been reported as partly predictive of COVID-19–related further deterioration, and their association has not been evaluated. We asked whether other key biomarkers of SARS-CoV-2 immunologic defects—increase in circulating immature granulocytes, loss of monocyte HLA-DR (mHLA-DR) expression, and monocyte differentiation blockade—could also predict further COVID-19 deterioration. A series of 284 consecutive COVID-19 patients, with the sole inclusion criterion of being an adult, were prospectively enrolled at emergency department admission (day 0) of 2 different hospitals: 1 for the exploratory cohort (180 patients) and 1 for the confirmatory cohort (104 patients). Deterioration was assessed over the next 7 days. Neither increased immature granulocyte levels nor monocyte differentiation blockade predicted patient worsening. Among more than 30 clinical, biological, and radiological parameters, the value of decreased P/F ratio and lymphopenia for prediction of further COVID-19 deterioration was strongly confirmed, and the loss of mHLA-DR was the only additional independent marker. Combined together in a simple OxyLymphoMono score, the 3 variables perfectly predicted patients who did not worsen and correctly predicted worsening in 59% of cases. By highlighting lymphocyte and monocyte defects as preceding COVID-19 deterioration, these results point on early immunosuppression in COVID-19 deterioration. Combining P/F ratio, lymphopenia, and loss of mHLA-DR together in a simple and robust score could offer a pragmatic method for COVID-19 patient stratification. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Along with PaO2/FiO2ratio and lymphopenia, low HLA-DR monocytes are the only additional parameter that independently predicts the clinical course of undifferentiated SARS-CoV-2 patients in emergency departments

Author

Lafon, Thomas, Chapuis, Nicolas, Guerin, Estelle, Daix, Thomas, Otranto, Marcela, Boumediene, Ahmed, Jeannet, Robin, Fontenay, Michaela, Henri Hani, Karam, Vignon, Philippe, Monneret, Guillaume, François, Bruno, Jean-Philippe, Jais, and Feuillard, Jean

Abstract

Because one-third of patients deteriorate after their admission to the emergency department, assessing the prognosis of COVID-19 patients is of great importance. However, to date, only lymphopenia and the partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) ratio have been reported as partly predictive of COVID-19–related further deterioration, and their association has not been evaluated. We asked whether other key biomarkers of SARS-CoV-2 immunologic defects—increase in circulating immature granulocytes, loss of monocyte HLA-DR (mHLA-DR) expression, and monocyte differentiation blockade—could also predict further COVID-19 deterioration. A series of 284 consecutive COVID-19 patients, with the sole inclusion criterion of being an adult, were prospectively enrolled at emergency department admission (day 0) of 2 different hospitals: 1 for the exploratory cohort (180 patients) and 1 for the confirmatory cohort (104 patients). Deterioration was assessed over the next 7 days. Neither increased immature granulocyte levels nor monocyte differentiation blockade predicted patient worsening. Among more than 30 clinical, biological, and radiological parameters, the value of decreased P/F ratio and lymphopenia for prediction of further COVID-19 deterioration was strongly confirmed, and the loss of mHLA-DR was the only additional independent marker. Combined together in a simple OxyLymphoMono score, the 3 variables perfectly predicted patients who did not worsen and correctly predicted worsening in 59% of cases. By highlighting lymphocyte and monocyte defects as preceding COVID-19 deterioration, these results point on early immunosuppression in COVID-19 deterioration. Combining P/F ratio, lymphopenia, and loss of mHLA-DR together in a simple and robust score could offer a pragmatic method for COVID-19 patient stratification.Preceding COVID-19 deterioration, increase in low HLA-DR monocytes points on early COVID-19 immunosuppression and, with lymphopenia, is the only independent biological parameter predicting COVID-19 worsening.

Published
2024
Full Text
View/download PDF

14. Neutralizing Antibody Levels as a Correlate of Protection Against SARS‐CoV‐2 Infection: A Modeling Analysis

Author

Lingas, Guillaume, primary, Planas, Delphine, additional, Péré, Hélène, additional, Porrot, Françoise, additional, Guivel‐Benhassine, Florence, additional, Staropoli, Isabelle, additional, Duffy, Darragh, additional, Chapuis, Nicolas, additional, Gobeaux, Camille, additional, Veyer, David, additional, Delaugerre, Constance, additional, Le Goff, Jérôme, additional, Getten, Prunelle, additional, Hadjadj, Jérôme, additional, Bellino, Adèle, additional, Parfait, Béatrice, additional, Treluyer, Jean‐Marc, additional, Schwartz, Olivier, additional, Guedj, Jérémie, additional, Kernéis, Solen, additional, and Terrier, Benjamin, additional

Published
2023
Full Text
View/download PDF

16. S162: LOSS OF HEMATOPOIETIC PROGENITORS HETEROGENEITY IS AN ADVERSE PROGNOSTIC FACTOR IN MYELODYSPLASTIC SYNDROMES

Author

Dussiau, Charles, primary, Comont, Thibault, additional, Knosp, Camille, additional, Vergnolle, Ines, additional, Bravetti, Clotilde, additional, Canali, Alban, additional, Houvert, Amandine, additional, Largeaud, Laetitia, additional, Daveaux, Christian, additional, Zaroili, Laila, additional, Friedrich, Chloe, additional, Boussaid, Ismael, additional, Zalmai, Loria, additional, Almire, Carole, additional, Beyne-Rauzy, Odile, additional, Willems, Lise, additional, Bouscary, Didier, additional, Gandrillon, Olivier, additional, Fontenay, Michaela, additional, Kosmider, Oliver, additional, Vergez, Francois, additional, and Chapuis, Nicolas, additional

Published
2023
Full Text
View/download PDF

19. Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis

Author

Vazquez, Romain, Breal, Claire, Zalmai, Loria, Friedrich, Chloe, Almire, Carole, Contejean, Adrien, Barreau, Sylvain, Grignano, Eric, Willems, Lise, Deau-Fischer, Benedicte, Franchi, Patricia, Vignon, Marguerite, Decroocq, Justine, Birsen, Rudy, Goldwirt, Lauriane, Kaltenbach, Sophie, Couronne, Lucile, Fontenay, Michaela, Kosmider, Olivier, Bouscary, Didier, and Chapuis, Nicolas

Published
2021
Full Text
View/download PDF

20. Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes

Author

Chesnais, Virginie, Arcangeli, Marie-Laure, Delette, Caroline, Rousseau, Alice, Guermouche, Hélène, Lefevre, Carine, Bondu, Sabrina, Diop, M'boyba, Cheok, Meyling, Chapuis, Nicolas, Legros, Laurence, Raynaud, Sophie, Willems, Lise, Bouscary, Didier, Lauret, Evelyne, Bernard, Olivier A., Kosmider, Olivier, Pflumio, Françoise, and Fontenay, Michaela

Published
2017
Full Text
View/download PDF

22. Neutralizing Antibody Levels as a Correlate of Protection Against SARS‐CoV‐2 Infection: A Modeling Analysis.

Author

Lingas, Guillaume, Planas, Delphine, Péré, Hélène, Porrot, Françoise, Guivel‐Benhassine, Florence, Staropoli, Isabelle, Duffy, Darragh, Chapuis, Nicolas, Gobeaux, Camille, Veyer, David, Delaugerre, Constance, Le Goff, Jérôme, Getten, Prunelle, Hadjadj, Jérôme, Bellino, Adèle, Parfait, Béatrice, Treluyer, Jean‐Marc, Schwartz, Olivier, Guedj, Jérémie, and Kernéis, Solen

Subjects
VIRAL load, POLYMERASE chain reaction, SARS-CoV-2, IMMUNOGLOBULINS, INFECTIOUS disease transmission, PLANT protection
Abstract

Although anti‐severe acute respiratory syndrome‐coronavirus 2 antibody kinetics have been described in large populations of vaccinated individuals, we still poorly understand how they evolve during a natural infection and how this impacts viral clearance. For that purpose, we analyzed the kinetics of both viral load and neutralizing antibody levels in a prospective cohort of individuals during acute infection with alpha variant. Using a mathematical model, we show that the progressive increase in neutralizing antibodies leads to a shortening of the half‐life of both infected cells and infectious viral particles. We estimated that the neutralizing activity reached 90% of its maximal level within 11 days after symptom onset and could reduce the half‐life of both infected cells and circulating virus by a 6‐fold factor, thus playing a key role to achieve rapid viral clearance. Using this model, we conducted a simulation study to predict in a more general context the protection conferred by pre‐existing neutralization titers, due to either vaccination or prior infection. We predicted that a neutralizing activity, as measured by 50% effective dose > 103, could reduce by 46% the risk of having viral load detectable by standard polymerase chain reaction assays and by 98% the risk of having viral load above the threshold of infectiousness. Our model shows that neutralizing activity could be used to define correlates of protection against infection and transmission. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Supplementary Figure Legend, Table 1 from Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia

Author

Chapuis, Nicolas, primary, Tamburini, Jerome, primary, Green, Alexa S., primary, Vignon, Christine, primary, Bardet, Valerie, primary, Neyret, Aymeric, primary, Pannetier, Melanie, primary, Willems, Lise, primary, Park, Sophie, primary, Macone, Alexandre, primary, Maira, Sauveur-Michel, primary, Ifrah, Norbert, primary, Dreyfus, François, primary, Herault, Olivier, primary, Lacombe, Catherine, primary, Mayeux, Patrick, primary, and Bouscary, Didier, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figures 1 - 4 from Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia

Author

Chapuis, Nicolas, primary, Tamburini, Jerome, primary, Green, Alexa S., primary, Vignon, Christine, primary, Bardet, Valerie, primary, Neyret, Aymeric, primary, Pannetier, Melanie, primary, Willems, Lise, primary, Park, Sophie, primary, Macone, Alexandre, primary, Maira, Sauveur-Michel, primary, Ifrah, Norbert, primary, Dreyfus, François, primary, Herault, Olivier, primary, Lacombe, Catherine, primary, Mayeux, Patrick, primary, and Bouscary, Didier, primary

Published
2023
Full Text
View/download PDF

25. Subcutaneous azacitidine maintenance in transplantineligible patients with acute myeloid leukemia: a single-center retrospective study

Author

Johnson, Natacha, primary, Templé, Marie, additional, Friedrich, Chloe, additional, Willems, Lise, additional, Birsen, Rudy, additional, Vignon, Marguerite, additional, Deschamps, Paul, additional, Franchi, Patricia, additional, Mondesir, Johanna, additional, Deau-Fischer, Benedicte, additional, Miekoutima, Elsa, additional, Boussaid, Ismaël, additional, Chapuis, Nicolas, additional, Kosmider, Olivier, additional, Bouscary, Didier, additional, Tamburini, Jerome, additional, and Decroocq, Justine, additional

Published
2023
Full Text
View/download PDF

27. Modelling the association between neutralizing antibody levels and SARS-CoV-2 viral dynamics : implications to define correlates of protection against infection

Author

Lingas, Guillaume, primary, Planas, Delphine, additional, Péré, Hélène, additional, Duffy, Darragh, additional, Staropoli, Isabelle, additional, Porrot, Françoise, additional, Guivel-Benhassine, Florence, additional, Chapuis, Nicolas, additional, Gobeaux, Camille, additional, Veyer, David, additional, Delaugerre, Constance, additional, Goff, Jérôme Le, additional, Getten, Prunelle, additional, Hadjadj, Jérôme, additional, Bellino, Adèle, additional, Parfait, Béatrice, additional, Treluyer, Jean-Marc, additional, Schwartz, Olivier, additional, Guedj, Jérémie, additional, Kernéis, Solen, additional, and Terrier, Benjamin, additional

Published
2023
Full Text
View/download PDF

28. Multiparameter flow cytometry in the evaluation of myelodysplasia:Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group

Author

Porwit, Anna, Béné, Marie C., Duetz, Carolien, Matarraz, Sergio, Oelschlaegel, Uta, Westers, Theresia M., Wagner-Ballon, Orianne, Kordasti, Shahram, Valent, Peter, Preijers, Frank, Alhan, Canan, Bellos, Frauke, Bettelheim, Peter, Burbury, Kate, Chapuis, Nicolas, Cremers, Eline, Della Porta, Matteo G., Dunlop, Alan, Eidenschink-Brodersen, Lisa, Font, Patricia, Fontenay, Michaela, Hobo, Willemijn, Ireland, Robin, Johansson, Ulrika, Loken, Michael R., Ogata, Kiyoyuki, Orfao, Alberto, Psarra, Katherina, Saft, Leonie, Subira, Dolores, te Marvelde, Jeroen, Wells, Denise A., van der Velden, Vincent H.J., Kern, Wolfgang, van de Loosdrecht, Arjan A., Porwit, Anna, Béné, Marie C., Duetz, Carolien, Matarraz, Sergio, Oelschlaegel, Uta, Westers, Theresia M., Wagner-Ballon, Orianne, Kordasti, Shahram, Valent, Peter, Preijers, Frank, Alhan, Canan, Bellos, Frauke, Bettelheim, Peter, Burbury, Kate, Chapuis, Nicolas, Cremers, Eline, Della Porta, Matteo G., Dunlop, Alan, Eidenschink-Brodersen, Lisa, Font, Patricia, Fontenay, Michaela, Hobo, Willemijn, Ireland, Robin, Johansson, Ulrika, Loken, Michael R., Ogata, Kiyoyuki, Orfao, Alberto, Psarra, Katherina, Saft, Leonie, Subira, Dolores, te Marvelde, Jeroen, Wells, Denise A., van der Velden, Vincent H.J., Kern, Wolfgang, and van de Loosdrecht, Arjan A.

Abstract

Multiparameter flow cytometry (MFC) is one of the essential ancillary methods in bone marrow (BM) investigation of patients with cytopenia and suspected myelodysplastic syndrome (MDS). MFC can also be applied in the follow-up of MDS patients undergoing treatment. This document summarizes recommendations from the International/European Leukemia Net Working Group for Flow Cytometry in Myelodysplastic Syndromes (ELN iMDS Flow) on the analytical issues in MFC for the diagnostic work-up of MDS. Recommendations for the analysis of several BM cell subsets such as myeloid precursors, maturing granulocytic and monocytic components and erythropoiesis are given. A core set of 17 markers identified as independently related to a cytomorphologic diagnosis of myelodysplasia is suggested as mandatory for MFC evaluation of BM in a patient with cytopenia. A myeloid precursor cell (CD34+CD19−) count >3% should be considered immunophenotypically indicative of myelodysplasia. However, MFC results should always be evaluated as part of an integrated hematopathology work-up. Looking forward, several machine-learning-based analytical tools of interest should be applied in parallel to conventional analytical methods to investigate their usefulness in integrated diagnostics, risk stratification, and potentially even in the evaluation of response to therapy, based on MFC data. In addition, compiling large uniform datasets is desirable, as most of the machine-learning-based methods tend to perform better with larger numbers of investigated samples, especially in such a heterogeneous disease as MDS.

Published
2023

29. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group

Author

Porwit, Anna, Béne, Marie C., Duetz, Carolien, Matarraz, Sergio, Oelschlaegel, Uta, Westers, Theresia M., Wagner-Ballon, Orianne, Kordasti, Sharham, Valent, Peter, Preijers, Frank W. M. B., Alhan, Canan, Bellos, Frauke, Bettelheim, Peter, Burbury, Kate, Chapuis, Nicolas, Cremers, Eline M. P., Della Porta, Matteo G., Dunlop, Alan, Eidenschink Brodersen, Lisa, Font, Patricia, Fontenay, Michaela, Hobo, Willemijn, Ireland, Robin, Johansson, Ulrika, Loken, Michael R., Ogata, Kiyoyuki, Orfao, Alberto, Psarra, Katherina, Saft, Leonie, Subirá, Dolores, Marvelde, Jeroen G. te, Wells, Denise A., Velden, Vincent H. J. van der, Kern, Wolfgang, Loosdrecht, Arjan A. Van De, Porwit, Anna, Béne, Marie C., Duetz, Carolien, Matarraz, Sergio, Oelschlaegel, Uta, Westers, Theresia M., Wagner-Ballon, Orianne, Kordasti, Sharham, Valent, Peter, Preijers, Frank W. M. B., Alhan, Canan, Bellos, Frauke, Bettelheim, Peter, Burbury, Kate, Chapuis, Nicolas, Cremers, Eline M. P., Della Porta, Matteo G., Dunlop, Alan, Eidenschink Brodersen, Lisa, Font, Patricia, Fontenay, Michaela, Hobo, Willemijn, Ireland, Robin, Johansson, Ulrika, Loken, Michael R., Ogata, Kiyoyuki, Orfao, Alberto, Psarra, Katherina, Saft, Leonie, Subirá, Dolores, Marvelde, Jeroen G. te, Wells, Denise A., Velden, Vincent H. J. van der, Kern, Wolfgang, and Loosdrecht, Arjan A. Van De

Abstract

Multiparameter flow cytometry (MFC) is one of the essential ancillary methods in bone marrow (BM) investigation of patients with cytopenia and suspected myelodysplastic syndrome (MDS). MFC can also be applied in the follow-up of MDS patients undergoing treatment. This document summarizes recommendations from the International/European Leukemia Net Working Group for Flow Cytometry in Myelodysplastic Syndromes (ELN iMDS Flow) on the analytical issues in MFC for the diagnostic work-up of MDS. Recommendations for the analysis of several BM cell subsets such as myeloid precursors, maturing granulocytic and monocytic components and erythropoiesis are given. A core set of 17 markers identified as independently related to a cytomorphologic diagnosis of myelodysplasia is suggested as mandatory for MFC evaluation of BM in a patient with cytopenia. A myeloid precursor cell (CD34+CD19−) count >3% should be considered immunophenotypically indicative of myelodysplasia. However, MFC results should always be evaluated as part of an integrated hematopathology work-up. Looking forward, several machine-learning-based analytical tools of interest should be applied in parallel to conventional analytical methods to investigate their usefulness in integrated diagnostics, risk stratification, and potentially even in the evaluation of response to therapy, based on MFC data. In addition, compiling large uniform datasets is desirable, as most of the machine-learning-based methods tend to perform better with larger numbers of investigated samples, especially in such a heterogeneous disease as MDS.

Published
2023

30. Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues—Recommendations from the European LeukemiaNet

Author

Austrian Science Fund, European Commission, Velden, Vincent H. J. van der, Preijers, Frank W. M. B., Johansson, Ulrika, Westers, Theresia M., Dunlop, Alan, Porwit, Anna, Béne, Marie C., Valent, Peter, Marvelde, Jeroen G. te, Wagner-Ballon, Orianne, Oelschlaegel, Uta, Saft, Leonie, Kordasti, Sharham, Ireland, Robin, Cremers, Eline M. P., Alhan, Canan, Duetz, Carolien, Hobo, Willemijn, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenschink Brodersen, Lisa, Font, Patricia, Loken, Michael R., Matarraz, Sergio, Ogata, Kiyoyuki, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise A., Della Porta, Matteo G., Burbury, Kate, Bellos, Frauke, Weiß, Elisabeth, Kern, Wolfgang, Austrian Science Fund, European Commission, Velden, Vincent H. J. van der, Preijers, Frank W. M. B., Johansson, Ulrika, Westers, Theresia M., Dunlop, Alan, Porwit, Anna, Béne, Marie C., Valent, Peter, Marvelde, Jeroen G. te, Wagner-Ballon, Orianne, Oelschlaegel, Uta, Saft, Leonie, Kordasti, Sharham, Ireland, Robin, Cremers, Eline M. P., Alhan, Canan, Duetz, Carolien, Hobo, Willemijn, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenschink Brodersen, Lisa, Font, Patricia, Loken, Michael R., Matarraz, Sergio, Ogata, Kiyoyuki, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise A., Della Porta, Matteo G., Burbury, Kate, Bellos, Frauke, Weiß, Elisabeth, and Kern, Wolfgang

Abstract

[Background]: Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years, significant progress has been made in the FCM field concerning technical issues (including software and hardware) and pre-analytical procedures. [Methods]: Recommendations are made based on the data and expert discussions generated from 13 yearly meetings of the European LeukemiaNet international MDS Flow working group. [Results]: We report here on the experiences and recommendations concerning (1) the optimal methods of sample processing and handling, (2) antibody panels and fluorochromes, and (3) current hardware technologies. [Conclusions]. These recommendations will support and facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients. Further standardization and harmonization will be required to integrate FCM in MDS diagnostic evaluations in daily practice.

Published
2023

31. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome:A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

Author

van de Loosdrecht, Arjan A., Kern, Wolfgang, Porwit, Anna, Valent, Peter, Kordasti, Sharham, Cremers, Eline, Alhan, Canan, Duetz, Carolien, Dunlop, Alan, Hobo, Willemijn, Preijers, Frank, Wagner-Ballon, Orianne, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenschink-Brodersen, Lisa, Font, Patricia, Johansson, Ulrika, Loken, Michael R., te Marvelde, Jeroen G., Matarraz, Sergio, Ogata, Kiyoyuki, Oelschlaegel, Uta, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise A., Béné, Marie C., Della Porta, Matteo G., Burbury, Kate, Bellos, Frauke, van der Velden, Vincent H.J., Westers, Theresia M., Saft, Leonie, Ireland, Robin, van de Loosdrecht, Arjan A., Kern, Wolfgang, Porwit, Anna, Valent, Peter, Kordasti, Sharham, Cremers, Eline, Alhan, Canan, Duetz, Carolien, Dunlop, Alan, Hobo, Willemijn, Preijers, Frank, Wagner-Ballon, Orianne, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenschink-Brodersen, Lisa, Font, Patricia, Johansson, Ulrika, Loken, Michael R., te Marvelde, Jeroen G., Matarraz, Sergio, Ogata, Kiyoyuki, Oelschlaegel, Uta, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise A., Béné, Marie C., Della Porta, Matteo G., Burbury, Kate, Bellos, Frauke, van der Velden, Vincent H.J., Westers, Theresia M., Saft, Leonie, and Ireland, Robin

Abstract

This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.

Published
2023

32. Flow cytometric analysis of myelodysplasia:Pre-analytical and technical issues—Recommendations from the European LeukemiaNet

Author

van der Velden, Vincent H.J., Preijers, Frank, Johansson, Ulrika, Westers, Theresia M., Dunlop, Alan, Porwit, Anna, Béné, Marie C., Valent, Peter, te Marvelde, Jeroen, Wagner-Ballon, Orianne, Oelschlaegel, Uta, Saft, Leonie, Kordasti, Sharham, Ireland, Robin, Cremers, Eline, Alhan, Canan, Duetz, Carolien, Hobo, Willemijn, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenshink-Brodersen, Lisa, Font, Patricia, Loken, Michael R., Matarraz, Sergio, Ogata, Kiyoyuki, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise A., Della Porta, Matteo G., Burbury, Kate, Bellos, Frauke, Weiß, Elisabeth, Kern, Wolfgang, van de Loosdrecht, Arjan, van der Velden, Vincent H.J., Preijers, Frank, Johansson, Ulrika, Westers, Theresia M., Dunlop, Alan, Porwit, Anna, Béné, Marie C., Valent, Peter, te Marvelde, Jeroen, Wagner-Ballon, Orianne, Oelschlaegel, Uta, Saft, Leonie, Kordasti, Sharham, Ireland, Robin, Cremers, Eline, Alhan, Canan, Duetz, Carolien, Hobo, Willemijn, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenshink-Brodersen, Lisa, Font, Patricia, Loken, Michael R., Matarraz, Sergio, Ogata, Kiyoyuki, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise A., Della Porta, Matteo G., Burbury, Kate, Bellos, Frauke, Weiß, Elisabeth, Kern, Wolfgang, and van de Loosdrecht, Arjan

Abstract

Background: Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years, significant progress has been made in the FCM field concerning technical issues (including software and hardware) and pre-analytical procedures. Methods: Recommendations are made based on the data and expert discussions generated from 13 yearly meetings of the European LeukemiaNet international MDS Flow working group. Results: We report here on the experiences and recommendations concerning (1) the optimal methods of sample processing and handling, (2) antibody panels and fluorochromes, and (3) current hardware technologies. Conclusions: These recommendations will support and facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients. Further standardization and harmonization will be required to integrate FCM in MDS diagnostic evaluations in daily practice.

Published
2023

33. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

Author

European Commission, Loosdrecht, Arjan A. Van De, Kern, Wolfgang, Porwit, Anna, Valent, Peter, Kordasti, Sharham, Cremers, Eline M. P., Alhan, Canan, Duetz, Carolien, Dunlop, Alan, Hobo, Willemijn, Preijers, Frank W. M. B., Wagner-Ballon, Orianne, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenschink-Brodersen, Lisa, Font, Patricia, Johansson, Ulrika, Loken, Michael R., Marvelde, Jeroen G. te, Matarraz, Sergio, Ogata, Kiyoyuki, Oelschlaegel, Uta, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise A., Béne, Marie C., Della Porta, Matteo G., Burbury, Kate, Bellos, Frauke, Velden, Vincent H. J. van der, Westers, Theresia M., Saft, Leonie, Ireland, Robin, European Commission, Loosdrecht, Arjan A. Van De, Kern, Wolfgang, Porwit, Anna, Valent, Peter, Kordasti, Sharham, Cremers, Eline M. P., Alhan, Canan, Duetz, Carolien, Dunlop, Alan, Hobo, Willemijn, Preijers, Frank W. M. B., Wagner-Ballon, Orianne, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenschink-Brodersen, Lisa, Font, Patricia, Johansson, Ulrika, Loken, Michael R., Marvelde, Jeroen G. te, Matarraz, Sergio, Ogata, Kiyoyuki, Oelschlaegel, Uta, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise A., Béne, Marie C., Della Porta, Matteo G., Burbury, Kate, Bellos, Frauke, Velden, Vincent H. J. van der, Westers, Theresia M., Saft, Leonie, and Ireland, Robin

Abstract

This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.

Published
2023

38. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition

Author

Jacque, Nathalie, Ronchetti, Anne Marie, Larrue, Clément, Meunier, Godelieve, Birsen, Rudy, Willems, Lise, Saland, Estelle, Decroocq, Justine, Maciel, Thiago Trovati, Lambert, Mireille, Poulain, Laury, Hospital, Marie Anne, Sujobert, Pierre, Joseph, Laure, Chapuis, Nicolas, Lacombe, Catherine, Moura, Ivan Cruz, Demo, Susan, Sarry, Jean Emmanuel, Recher, Christian, Mayeux, Patrick, Tamburini, Jérôme, and Bouscary, Didier

Published
2015
Full Text
View/download PDF

39. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues

Author

Porwit, Anna, primary, Béné, Marie C., additional, Duetz, Carolien, additional, Matarraz, Sergio, additional, Oelschlaegel, Uta, additional, Westers, Theresia M., additional, Wagner‐Ballon, Orianne, additional, Kordasti, Shahram, additional, Valent, Peter, additional, Preijers, Frank, additional, Alhan, Canan, additional, Bellos, Frauke, additional, Bettelheim, Peter, additional, Burbury, Kate, additional, Chapuis, Nicolas, additional, Cremers, Eline, additional, Della Porta, Matteo G., additional, Dunlop, Alan, additional, Eidenschink‐Brodersen, Lisa, additional, Font, Patricia, additional, Fontenay, Michaela, additional, Hobo, Willemijn, additional, Ireland, Robin, additional, Johansson, Ulrika, additional, Loken, Michael R., additional, Ogata, Kiyoyuki, additional, Orfao, Alberto, additional, Psarra, Katherina, additional, Saft, Leonie, additional, Subira, Dolores, additional, te Marvelde, Jeroen, additional, Wells, Denise A., additional, van der Velden, Vincent H. J., additional, Kern, Wolfgang, additional, and van de Loosdrecht, Arjan A., additional

Published
2022
Full Text
View/download PDF

40. AML MRD By Multiparameter Flow Cytometry Using Laip/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network

Author

Plesa, Adriana, primary, Dumezy, Florent, additional, Mathis, Stéphanie, additional, Lhoumeau, Anne-Catherine, additional, Bardet, Valerie, additional, Saada, Véronique, additional, Arnoux, Isabelle, additional, Badaoui, Bouchra, additional, Cornet, Edouard, additional, Osman, Jennifer, additional, Guerin, Estelle, additional, Chapuis, Nicolas, additional, Genevieve, Franck, additional, Letestu, Rémi, additional, Manzoni, Delphine, additional, Roggy, Anne, additional, Roussel, Mikael, additional, Harrivel, Véronique, additional, Bera, Elsa, additional, Mayeur-Rousse, Caroline, additional, Lapillonne, Hélène, additional, Veyrat-Masson, Richard, additional, Campos, Lydia, additional, Le Garff-Tavernier, Magali, additional, Raskovalova, Tatiana, additional, Vergez, Francois, additional, Guy, Julien, additional, Charpentier, Agnes, additional, Hemar, Claire, additional, Goncalves Monteiro, Valerie, additional, Fegier, Frederic, additional, Celli-Lebras, Karine, additional, Itzykson, Raphael, additional, Dombret, Herve, additional, Preudhomme, Claude, additional, and Roumier, Christophe, additional

Published
2022
Full Text
View/download PDF

41. Rare PNH Cells May be Considered As Genuine PNH Clone: Insights from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study

Author

Le Garff-Tavernier, Magali, primary, Vial, Jean-Philippe, additional, Boyer, Thomas, additional, Chapuis, Nicolas, additional, Harrivel, Véronique, additional, Lhoumeau, Anne-Catherine, additional, Bera, Elsa, additional, Kittler, Isabelle, additional, Loosveld, Marie, additional, Socie, Gerard, additional, Peffault de Latour, Régis, additional, Drenou, Bernard, additional, Debliquis, Agathe, additional, and Wagner-Ballon, Orianne, additional

Published
2022
Full Text
View/download PDF

42. DNA Replication Stress Due to Loss of R-Loops in Myelodysplastic Syndromes with SF3B1 Mutation

Author

Rombaut, David, primary, Lefevre, Carine, additional, Farhat, Batoul, additional, Bondu, Sabrina, additional, Letessier, Anne, additional, Lesieur-Pasquier, Auriane, additional, Castillo-Guzman, Daisy, additional, Leduc, Marjorie, additional, Gautier, Emilie-Fleur, additional, Chesnais, Virginie, additional, Rousseau, Alice, additional, Boussaid, Ismael, additional, Battault, Sarah, additional, Houy, Alexandre, additional, Bouscary, Didier, additional, Willems, Lise, additional, Chapuis, Nicolas, additional, Park, Sophie, additional, Raynaud, Sophie, additional, Cluzeau, Thomas, additional, Clappier, Emmanuelle, additional, Fenaux, Pierre, additional, Ades, Lionel, additional, Solary, Eric, additional, Margueron, Raphael, additional, Wassef, Michel, additional, Kosmider, Olivier, additional, Alsafadi, Samar, additional, Droin, Nathalie, additional, Constantinou, Angelos, additional, Stern, Marc-Henri, additional, Miotto, Benoit, additional, Chedin, Frederic, additional, and Fontenay, Michaela, additional

Published
2022
Full Text
View/download PDF

43. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

Author

Loosdrecht, Arjan, Kern, Wolfgang, Porwit, Anna, Valent, Peter, Kordasti, Sharham, Cremers, Eline, Alhan, Canan, Duetz, Carolien, Dunlop, Alan, Hobo, Willemijn, Preijers, Frank, Wagner‐ballon, Orianne, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenschink‐brodersen, Lisa, Font, Patricia, Johansson, Ulrika, Loken, Michael, Marvelde, Jeroen, Matarraz, Sergio, Ogata, Kiyoyuki, Oelschlaegel, Uta, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise, Béné, Marie, Della Porta, Matteo, Burbury, Kate, Bellos, Frauke, Velden, Vincent, Westers, Theresia, Saft, Leonie, Ireland, Robin, MUMC+: MA Med Staf Artsass Interne Geneeskunde (9), RS: FHML non-thematic output, Amsterdam UMC - Amsterdam University Medical Center, Munich Leukemia Laboratory [Munich, Germany] (M2L), Lund University [Lund], Medizinische Universität Wien = Medical University of Vienna, King‘s College London, Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht], The Royal Marsden, Radboud University Medical Center [Nijmegen], Hôpital Henri Mondor, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Ordensklinikum Linz Elisabethinen, HematoLogics, Inc. [Seattle, WA, USA], Hospital General Universitario 'Gregorio Marañón' [Madrid], University Hospitals Bristol, Erasmus University Medical Center [Rotterdam] (Erasmus MC), Universidad de Salamanca, Metropolitan Research and Treatment Centre for Blood Disorders [Tokyo, Japan] (MRTC Japan), University Hospital Carl Gustav Carus [Dresden, Germany], Technische Universität Dresden = Dresden University of Technology (TU Dresden), Evangelismos Athens General Hospital, Universidad de Guadalajara, Immunobiology of Human αβ and γδ T Cells and Immunotherapeutic Applications (CRCINA-ÉQUIPE 1), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre hospitalier universitaire de Nantes (CHU Nantes), Humanitas University [Milan] (Hunimed), Istituto Clinico Humanitas [Milan] (IRCCS Milan), University of Melbourne, Karolinska Institutet [Stockholm], King's College Hospital (KCH), Hematology, CCA - Cancer biology and immunology, Internal medicine, Hematology laboratory, Immunology, and Bernardo, Elizabeth

Subjects
standardization, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], flow cytometry, CONSORTIUM, [SDV.CAN]Life Sciences [q-bio]/Cancer, PROGNOSTIC SCORING SYSTEM, DIAGNOSIS, CYTOGENETICS, myelodysplastic syndromes, CLASSIFICATION, VALIDATION, All institutes and research themes of the Radboud University Medical Center, [SDV.CAN] Life Sciences [q-bio]/Cancer, consensus, hemic and lymphatic diseases, CELLS, SUBGROUPS, ELN, CYTOMORPHOLOGY
Abstract

Contains fulltext : 290800.pdf (Publisher’s version ) (Open Access) This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients. 01 januari 2023

Published
2023

46. Plasma Endocan as a Biomarker of Thrombotic Events in COVID-19 Patients

Author

Chenevier-Gobeaux, Camille, primary, Ducastel, Morgane, additional, Meritet, Jean-François, additional, Ballaa, Yassine, additional, Chapuis, Nicolas, additional, Pene, Frédéric, additional, Carlier, Nicolas, additional, Roche, Nicolas, additional, Szwebel, Tali-Anne, additional, Terrier, Benjamin, additional, and Borderie, Didier, additional

Published
2022
Full Text
View/download PDF

48. Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia

Author

Willems, Lise, Jacque, Nathalie, Jacquel, Arnaud, Neveux, Nathalie, Trovati Maciel, Thiago, Lambert, Mireille, Schmitt, Alain, Poulain, Laury, Green, Alexa S., Uzunov, Madalina, Kosmider, Olivier, Radford-Weiss, Isabelle, Moura, Ivan Cruz, Auberger, Patrick, Ifrah, Norbert, Bardet, Valérie, Chapuis, Nicolas, Lacombe, Catherine, Mayeux, Patrick, Tamburini, Jérôme, and Bouscary, Didier

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results